HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.
Chronic hepatitis C virus (HCV) infection has become a major threat to the survival of human immunodeficiency virus (HIV)-infected persons in areas where antiretroviral therapy is available. In coinfection, viral eradication has been difficult to attain, and HCV therapy is underused. Novel therapies may be particularly beneficial for this population, yet studies lag behind those for HCV monoinfection. Increasingly, incident HCV among HIV-infected men who have sex with men is associated with sexual risk behavior further research should be performed to refine understanding of the causal mechanism of this association. The phenomenon of aggressive hepatic fibrogenesis when HIV infection precedes HCV acquisition requires longer-term observation to ensure optimal timing of HCV therapy. Medical management in coinfection will be improved by enhancing HCV detection, with annual serologic testing, screening with HCV RNA to detect acute infection, and HIV testing of HCV-infected individuals; by addressing HCV earlier in coinfected persons; and by universal consideration for HCV therapy. HCV drug trials in individuals coinfected with HIV should be expedited. HIV/HCV coinfection remains a growing and evolving epidemic; new developments in therapeutics and improved care models offer promise.
Department of Medicine, Brown University, Providence, RI 02906, USA. LTaylor@Lifespan.org
Lynn E
LE
Taylor
Tracy
T
Swan
Kenneth H
KH
Mayer
D000998:Antiviral Agents / Q000627:therapeutic use; D060085:Coinfection; D018450:Disease Progression; D006678:HIV / Q000472:pathogenicity; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology* / Q000821:virology; D016174:Hepacivirus / Q000472:pathogenicity*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D015994:Incidence; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology / Q000821:virology; D008403:Mass Screening / Q000379:methods; D011392:Proline / Q000031:analogs & derivatives / Q000494:pharmacology; D012367:RNA, Viral / Q000097:blood*; D012309:Risk-Taking; D012725:Sexual Behavior
D000998:Antiviral Agents; D012367:RNA, Viral; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline